Oligometastatic Prostate Cancer Clinical Trial
Official title:
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
This study aims to probe the effect of SBRT as a treatment oligometastases of prostate cancer, regardless of basal treatment received, and I know the response, biochemical control, the progression-free survival as well as their impact on quality of life. Primary Objective: Local and symptomatic oligometastases Control of prostate cancer treated by SBRT. Secondary Objectives: Analyzing biochemical progression rates, progression-free survival, chemotherapy-free survival and overall survival. Analyze toxicities and quality of life of patients before and after treatment
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03940235 -
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
|
Phase 2 | |
| Completed |
NCT01859221 -
Radiotherapy for Oligometastatic Prostate Cancer
|
N/A | |
| Recruiting |
NCT06060652 -
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
|
||
| Recruiting |
NCT04610372 -
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
|
N/A | |
| Recruiting |
NCT05915442 -
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04992026 -
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05560659 -
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
|
Phase 2 | |
| Recruiting |
NCT06387056 -
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
|
Phase 2 |